NCT06203470
Botox Versus Tacrolimus in Psoriasis Vulgaris
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Jun 2024); last known: Not Yet Recruiting
Notable Primary endpoint revisedv2 Show 4 more changesShow less
- Interventions: Botulinum Toxin-A (Drug), calcipotriol (Drug) to Botulinum Toxin-A (Drug), Tacrolimus (Drug)
- Publications revised (17)
- Study title revised
- Study description shortened, about 1 word
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (2)
Arms and interventions
Patients will receive a single intradermal injection of Mesobotox as a monotherapy. Botulinum toxin injection: Botox injections will be intradermal. Concentration will be 100 U to be diluted with 5-ml sterile physiological sodium chloride solution. Each patient will receive individual injections of 1 U using a grid with points set at a distance of 1 cm apart. Up to two plaques per patient will be selected, whose diameter would not exceed 5-10 cm2. Each patient will receive a single BoNT-A injection
Patients will receive a single intradermal injection of Mesobotox of the same dilution followed by topical application of Tacrolimus 0.03% ointment twice daily for 3 months.
Patients will apply Tacrolimus (0.03%) as a monotherapeutic twice daily for 3 months
Drugs: Botulinum Toxin-A, Tacrolimus